Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
7.11
Dollar change
-0.54
Percentage change
-7.06
%
Index- P/E- EPS (ttm)-3.55 Insider Own13.03% Shs Outstand62.92M Perf Week-19.30%
Market Cap450.35M Forward P/E- EPS next Y-2.92 Insider Trans0.00% Shs Float55.09M Perf Month-30.16%
Income-191.85M PEG- EPS next Q-0.74 Inst Own31.78% Short Float0.88% Perf Quarter-38.07%
Sales0.00M P/S- EPS this Y21.30% Inst Trans-2.67% Short Ratio3.88 Perf Half Y-47.64%
Book/sh2.15 P/B3.30 EPS next Y-0.95% ROA-78.06% Short Interest0.48M Perf Year-31.70%
Cash/sh3.76 P/C1.89 EPS next 5Y- ROE-171.78% 52W Range7.65 - 17.02 Perf YTD-33.55%
Dividend Est.- P/FCF- EPS past 5Y-15.12% ROI-95.44% 52W High-58.23% Beta0.27
Dividend TTM- Quick Ratio3.04 Sales past 5Y0.00% Gross Margin- 52W Low-7.06% ATR (14)0.47
Dividend Ex-Date- Current Ratio3.04 EPS Y/Y TTM-4.53% Oper. Margin- RSI (14)26.58 Volatility5.52% 5.30%
Employees61 Debt/Eq0.78 Sales Y/Y TTM- Profit Margin- Recom1.17 Target Price32.44
Option/ShortNo / Yes LT Debt/Eq0.48 EPS Q/Q10.31% Payout- Rel Volume2.25 Prev Close7.65
Sales Surprise62.16% EPS Surprise-3.76% Sales Q/Q- EarningsNov 07 BMO Avg Volume125.08K Price7.11
SMA20-16.62% SMA50-25.06% SMA200-42.17% Trades Volume281,343 Change-7.06%
Date Action Analyst Rating Change Price Target Change
Dec-04-24Initiated JMP Securities Mkt Outperform $33
Jul-29-24Initiated Laidlaw Buy $48
May-20-24Initiated BTIG Research Buy $43
Apr-29-24Initiated Piper Sandler Overweight $42
Apr-29-24Initiated Guggenheim Buy $50
Nov-14-23Initiated Morgan Stanley Equal-Weight $15
Nov-14-23Initiated Leerink Partners Outperform $20
Nov-19-24 04:30PM
Nov-14-24 04:01PM
Nov-13-24 04:01PM
Oct-07-24 04:01PM
Oct-03-24 04:01PM
02:31AM Loading…
02:31AM
Sep-26-24 02:30AM
Sep-25-24 04:01PM
Sep-09-24 04:01PM
Aug-06-24 02:30AM
Jul-15-24 04:00PM
Jun-04-24 04:10PM
May-08-24 02:30AM
May-07-24 04:00PM
Apr-05-24 04:00PM
02:30AM Loading…
Apr-02-24 02:30AM
Feb-13-24 02:50AM
Feb-07-24 02:30AM
Feb-02-24 02:30AM
Jan-24-24 02:30AM
Jan-22-24 02:30AM
Jan-04-24 02:30AM
Nov-21-23 02:30AM
Nov-14-23 08:00AM
Oct-24-23 04:15PM
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.